ArticleScientific reports2026
TM4SF1 mediates YAP/TAZ regulation of coronary artery formation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Although the role of YAP/TAZ in mediating VEGF-driven angiogenesis is well established, their downstream effectors in coronary artery development remain elusive. In this study, we identify TM4SF1 as a novel downstream target of YAP/TAZ in coronary endothelial cells. Conditional deletion of YAP/TAZ in the endocardial lineage resulted in embryonic lethality due to congenital heart defects, including ventricular noncompaction. Mutant embryos exhibited severe coronary vessel defects, including the absence of major arteries. Loss of YAP/TAZ significantly inhibited endothelial cell proliferation and coronary angiogenesis. Transcriptomic profiling revealed that YAP/TAZ deficiency downregulated the expression of TM4SF1, a known regulator of angiogenesis, in the endocardium and coronary endothelium. Consistently, YAP/TAZ were required for VEGF-induced upregulation of TM4SF1 in endothelial cells. Moreover, YAP/TAZ-mediated upregulation of TM4SF1 was essential for VEGF-driven angiogenesis in HUVECs. Together, these findings indicate that TM4SF1 functions downstream of YAP/TAZ to regulate endothelial angiogenic processes, suggesting a potential role for TM4SF1 in coronary artery development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.